Diabetes and Nutritional Sciences Division, School of Medicine, Kingrsquos College London, London SE1 9NH, United Kingdom.
J Lipid Res. 2013 Feb;54(2):542-51. doi: 10.1194/jlr.P032276. Epub 2012 Nov 15.
Delta-5 and delta-6 desaturases (D5D and D6D) are key enzymes in endogenous synthesis of long-chain PUFAs. In this sample of healthy subjects (n = 310), genotypes of single nucleotide polymorphisms (SNPs) rs174537, rs174561, and rs3834458 in the FADS1-FADS2 gene cluster were strongly associated with proportions of LC-PUFAs and desaturase activities estimated in plasma and erythrocytes. Minor allele carriage associated with decreased activities of D5D (FADS1) (5.84 × 10(-19) ≤ P ≤ 4.5 × 10(-18)) and D6D (FADS2) (6.05 × 10(-8) ≤ P ≤ 4.20 × 10(-7)) was accompanied by increased substrate and decreased product proportions (0.05 ≤ P ≤ 2.49 × 10(-16)). The significance of haplotype association with D5D activity (P = 2.19 × 10(-17)) was comparable to that of single SNPs, but haplotype association with D6D activity (P = 3.39 × 10(-28)) was much stronger. In a randomized controlled dietary intervention, increasing eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) intake significantly increased D5D (P = 4.0 × 10(-9)) and decreased D6D activity (P = 9.16 × 10(-6)) after doses of 0.45, 0.9, and 1.8 g/day for six months. Interaction of rs174537 genotype with treatment was a determinant of D5D activity estimated in plasma (P = 0.05). In conclusion, different sites at the FADS1-FADS2 locus appear to influence D5D and D6D activity, and rs174537 genotype interacts with dietary EPA+DHA to modulate D5D.
德尔塔-5 和德尔塔-6 去饱和酶(D5D 和 D6D)是内源性长链多不饱和脂肪酸合成的关键酶。在本研究中,对 310 名健康受试者的单核苷酸多态性(SNP)rs174537、rs174561 和 rs3834458 基因型与血浆和红细胞中 LC-PUFA 比例和去饱和酶活性进行了分析。D5D(FADS1)(5.84×10(-19)≤P≤4.5×10(-18))和 D6D(FADS2)(6.05×10(-8)≤P≤4.20×10(-7))活性降低的等位基因携带与底物比例增加和产物比例降低相关(0.05≤P≤2.49×10(-16))。D5D 活性与单核苷酸多态性(SNP)的关联显著(P=2.19×10(-17)),与单核苷酸多态性(SNP)的关联具有可比性,但 D6D 活性与单核苷酸多态性(SNP)的关联更为显著(P=3.39×10(-28))。在一项随机对照饮食干预中,摄入更多的二十碳五烯酸(EPA,20:5n-3)和二十二碳六烯酸(DHA,22:6n-3)可显著增加 D5D(P=4.0×10(-9))并降低 D6D 活性(P=9.16×10(-6)),为期六个月,剂量分别为 0.45、0.9 和 1.8 g/天。rs174537 基因型与治疗之间的相互作用是影响血浆中 D5D 活性的决定因素(P=0.05)。总之,FADS1-FADS2 基因座的不同位点似乎影响 D5D 和 D6D 的活性,并且 rs174537 基因型与饮食 EPA+DHA 相互作用,调节 D5D。